NDA 20-475/S-008

Johnson & Johnson Consumer Companies, Inc
Attention: George Latyszonek
Director, Regulatory Affairs
199 Grandview Avenue
Skillman, NJ 08558

Dear Mr. Latyszonek:

Please refer to your supplemental new drug application dated July 12, 2001, received July 12, 2001, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Retin-A MICRO (tretinoin gel) microspheres, 0.04%.

We acknowledge receipt of your submissions dated September 24 and 25, October 2, December 21, 2001; February 13, March 6 and 25, April 1, 15, and 23. In addition, via email dated May 7, 8, (two emails), 9, and 10, 2002; facsimiles dated May 10 (two), 2002.

This supplemental new drug application provides for a lower strength of tretinoin gel and is indicated for topical application for the treatment of acne vulgaris

We have completed the review of this supplemental application, as amended, and have concluded that adequate information has been presented to demonstrate that the drug products are safe and effective for use as recommended in the agreed upon labeling text. Accordingly, the supplemental application is approved effective on the date of this letter.

The final printed labeling (FPL) must be identical to the enclosed draft labeling (package insert, patient package insert, immediate container and carton labels).

Please submit the copies of final printed labeling (FPL) electronically according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format - NDA* (January 1999). Alternatively, you may submit 20 paper copies of the FPL as soon as it is available but no more than 30 days after it is printed. Please individually mount ten of the copies on heavy-weight paper or similar material. For administrative purposes, this submission should be designated "FPL for approved supplement NDA 20-475/S-008." Approval of this submission by FDA is not required before the labeling is used.

Be advised that, as of April 1, 1999, all applications for new active ingredients, new dosage forms, new indications, new routes of administration, and new dosing regimens are required to contain as assessment of the safety and effectiveness of the product in pediatric patients unless this requirement is waived or deferred (63 *FR* 66632).

We are waiving the pediatric study requirement for this application, as the necessary studies for 12- year-olds and above have been done, and no studies for the indication of treatment of acne vulgaris are needed in the less than 12-year-old pediatric population.

In addition, please submit three copies of the introductory promotional materials that you propose to use for these products. All proposed materials should be submitted in draft or mock-up form, not final print. Please submit one copy to this Division and two copies of both the promotional materials and the package inserts directly to:

Division of Drug Marketing, Advertising, and Communications, HFD-42
Food and Drug Administration
5600 Fishers Lane
Rockville, Maryland 20857

If a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter) is issued to physicians and others responsible for patient care, we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HF-2
FDA
5600 Fishers Lane
Rockville, MD 20857

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

We, also, remind you of your postmarketing study commitments in you facsimile transmissions dated May 10, 2002. These commitments are listed below:

1) A dose ranging study, comparing the safety and efficacy of both 0.04% and 0.1% concentrations of Retin-A MICRO.

   Protocol Submission: Within 6 months of the date of this letter.
   Final Study Reports: Within 3 ½ years of the date of this letter.

An additional agreed upon postmarketing study commitment, listed in the original approval letter for NDA 20-475, dated February 7, 1997, has not yet been fulfilled. Since there was a positive outcome in one of the genetic toxicology tests of EGDMA, per the original commitment a dermal carcinogenicity study of the Retin-A MICRO (0.1% tretinoin) formulation will be performed.

If you have any questions, please call Kalyani Bhatt, Project Manager, at (301) 827-2020.

Sincerely,

*{See appended electronic signature page}*

Jonathan K. Wilkin, M.D.
Director
Division of Dermatologic & Dental Drug Products
Office of Drug Evaluation V
Center for Drug Evaluation and Research

Enclosure

---

**This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.**

---

/s/

---

Jonathan Wilkin

5/10/02 08:09:55 PM